Anti-RIG-I/DDX58 antibody [EPR26465-40]
- 20ul selling size
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(2 Publications)
Rabbit Recombinant Monoclonal RIG-I/DDX58 antibody. Suitable for WB, ICC/IF, IP and reacts with Mouse samples. Cited in 2 publications.
View Alternative Names
Ddx58, Rigi, Antiviral innate immune response receptor RIG-I, ATP-dependent RNA helicase DDX58, DEAD box protein 58, RIG-I-like receptor 1, RNA sensor RIG-I, Retinoic acid-inducible gene 1 protein, Retinoic acid-inducible gene I protein, RLR-1, RIG-1, RIG-I
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-RIG-I/DDX58 antibody [EPR26465-40] (AB302778)
Immunocytochemical/Immunofluorescence analysis of 4% paraformaldehyde fixed, and 0.1% Triton X-100 permeabilized RAW 264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) cells labeling RIG-I/DDX58 with ab302778 at 1/500 dilution (1.082 μg/ml), followed by preabsorbed ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution (2 μg/mL)(Green). Confocal image showing increased cytoplasmic staining in RAW 264.7 cells treated with lipopolysaccharide (1 μg/mL) for 16 h. Counterstained with ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) at 1/200 dilution (2.5 μg/ml) (Red).
- IP
Supplier Data
Immunoprecipitation - Anti-RIG-I/DDX58 antibody [EPR26465-40] (AB302778)
RIG-I/DDX58 was immunoprecipitated from 0.35 mg RAW 264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate with ab302778 at 1/30 dilution (2 µg in 0.35 mg lysates). Western blot was performed on the immunoprecipitate using ab302778 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution. Lane 1 : RAW 264.7 whole cell lysate 10 μg Lane 2 : ab302778 IP in RAW264.7 whole cell lysate Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab302778 in RAW264.7 whole cell lysate Blocking and dilution buffer : 5% NFDM/TBST. Exposure time : 128 seconds. Observed MW (kDa) : 102, 80.
All lanes:
Immunoprecipitation - Anti-RIG-I/DDX58 antibody [EPR26465-40] (ab302778) at 1/30 dilution
All lanes:
RAW264.7 whole cell lysate
Secondary
All lanes:
Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/5000 dilution
Observed band size: 102 kDa,80 kDa
false
Exposure time: 128s
- WB
Supplier Data
Western blot - Anti-RIG-I/DDX58 antibody [EPR26465-40] (AB302778)
Blocking and dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-RIG-I/DDX58 antibody [EPR26465-40] (ab302778) at 1/1000 dilution
Lane 1:
NIH/3T3 (mouse embryonic fibroblast) whole cell lysate at 20 µg
Lane 2:
Mouse spleen tissue lysate at 20 µg
Lane 3:
Mouse pancreas tissue lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Observed band size: 102 kDa
false
Exposure time: 3min
- WB
Supplier Data
Western blot - Anti-RIG-I/DDX58 antibody [EPR26465-40] (AB302778)
Blocking and dilution buffer : 5% NFDM/TBST. The expression of RIG-I/DDX58 is upregulated in response to LPS treatment (PMID : 18523264). The expression molecular weight observed is consistent with what has been described in the literature (PMID : 29346611).
All lanes:
Western blot - Anti-RIG-I/DDX58 antibody [EPR26465-40] (ab302778) at 1/1000 dilution
Lane 1:
Untreated RAW 264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate at 20 µg
Lane 2:
RAW 264.7 treated with 1ug/ml LPS (lipopolysaccharide) for 16 hours, whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Observed band size: 102 kDa,80 kDa
false
Exposure time: 26s
Related conjugates and formulations (1)
-
Anti-RIG-I/DDX58 antibody [EPR26465-40] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
RIG-I contributes significantly to the innate immune response. It acts to sense viral RNA and triggers the production of type I interferons and other pro-inflammatory cytokines. This protein functions as part of a complex that includes MAVS (mitochondrial antiviral signaling protein) and other signaling adapters. Upon activation RIG-I undergoes a conformational change leading to the exposure of its CARDs which interact with CARDs of MAVS facilitating downstream signaling to induce an antiviral state in host cells.
Pathways
RIG-I plays a central role in the RNA sensing pathway critical for antiviral immunity. This pathway involves several steps beginning with the recognition of viral RNA leading to the activation of interferon regulatory factors like IRF3 and IRF7 as well as nuclear factor kappa B (NF-κB). These factors then promote the expression of interferon-stimulated genes (ISGs). RIG-I also relates closely to the Jak-STAT signaling pathway which is activated by interferons and enhances the transcription of ISGs further amplifying the antiviral response.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Biochemical genetics : PubMed40392448
2025
Applications
Unspecified application
Species
Unspecified reactive species
iScience 26:108463 PubMed38187191
2024
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com